Efficacy of 5% tranexamic acid in melasma
DOI:
https://doi.org/10.66344/jpad.v33i4.2449Keywords:
Tranexamic acid, MelasmaAbstract
Objective To determine the efficacy of topical 5% tranexamic acid cream in patients of melasma.
Methods Total 100 patients of either gender with clinical diagnosis of melasma were enrolled in the study after taking informed written consent. The demographic data was collected on a pre-designed proforma. Baseline modified MASI score was calculated and pictures were taken of all patients at baseline. The patients were advised to apply 5% topical tranexamic acid cream at night along with sunscreen during day time for 12 weeks daily. All patients were evaluated for improvement of melasma using percentage reduction in MASI score at the end of 12 weeks and pictures were also taken again.
Results The patients' average age was 29.23 6.58 years. With a male to female ratio of 0.2:1, there were 100 patients, 81 of whom were female, and 19 who were male. At the conclusion of 12 weeks, the modified MASI score had decreased by a mean of 41.4314.56. After 12 weeks, the modified MASI score was reduced by less than 50% in 63% of patients whereas it was reduced by more than 50% in 37% of patients. In our study, 37 (37%) patients experienced efficacy.
Conclusion This study concluded that the topical 5% tranexamic acid cream was effective in 37% of melasma patients in our study population (>50% reduction in baseline Modified MASI score) after 12 weeks.
References
1. Rodrigues M, Ayala-Cortés AS, Rodríguez-Arámbula A, Hynan LS, Pandya AG. Interpretability of the modified melasma area and severity index (mMASI). JAMA dermatology 2016;152(9):1051-2
2. Grimes P, Ijaz S, Nashawati R, Kwak D. New oral and topical approaches for the treatment of melasma. International journal of women's dermatology 2019;5(1):30-6. 3.
3. Basit H, Godse KV, Al Aboud AM. Melasma. Treasure Island (FL): StatPearls Publishing. 2019.
4. Melasma:a clinico-epidemiological study of 312cases.Indian J Dermatol2011;56:380-2
5. Padhi T, Pradhan S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: An open labeled randomized comparative trial. Indian journal of dermatology 2015;60(5):520.
6. Wu S, Shi H, Wu H, et al. Treatment of melasma with oral administration of tranexamic acid. Aesthetic Plast Surg. 2012;36(4):964–970. doi: 10.1007/s00266-012-9899-9
7. Kanechorn Na Ayuthaya P, Niumphradit N, Manosroi A, Nakakes A. Topical 5% tranexamic acid for the treatment of melasma in Asians: a double-blind randomized controlled clinical trial. J Cosmet Laser Ther. 2012; 14(3):150–154.
8. Lake E. JAAD Game Changers: Oral tranexamic acid (TA) in the treatment of melasma: A retrospective analysis. Journal of the American Academy of Dermatology 2019;80(3):833.
9. Khuraiya S, Kachhawa D, Chouhan B, Dua M, Rao P. A comparative study of topical 5% tranexamic acid and triple combination therapy for the treatment of melasma in Indian population. Pigment International 2019;6(1):18.
10. Del Rosario E, Florez-Pollack S, Zapata Jr L, Hernandez K, Tovar-Garza A, Rodrigues M, et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. Journal of the American Academy of Dermatology 2018;78(2):363-9.
11. Janney MS, Subramaniyan R, Dabas R, Lal S, Das NM, Godara SK. A randomized controlled study comparing the efficacy of topical 5% tranexamic acid solution versus 3% hydroquinone cream in melasma. Journal of cutaneous and aesthetic surgery 2019;12(1):63.
12. Karen JK, Pomeranz MK. Skin changes and diseases in pregnancy.In:Wolff K,Goldsmith LA,Katz SI,GilchrestBA, PallerAS,Leffel DJ,editors.Dermatology in General Medicine,7th ed. New york:McGraw-Hill;2008.P.955-62
13. Nijor T. Treatment of melasma with tranexamic acid. Clin Res 1979;13(13):3129-31.
14. Sheth VM, Pandya AG. Melasma: a comprehensive update: part II. Journal of the American Academy of Dermatology 2011;65(4):699-714.
15. Singh R, Goyal S, Ahmed QR, Gupta N,Singh S. Effect of 82% lactic acid intreatment of melasma. Int Scholarly ResNotices. 2014;7:1-7.
16. ZhangL, Tan W-Q, Fang Q-Q, Zhao W-Y, Zhao Q-M, Gao J, et al. Tranexamic acid for adults with melasma: a systematic review and meta-analysis. BioMed research international 2018;2018.
17. Sarvjot V, Sharma S, Mishra S, Singh A.Melasma: A clinicopathological study of 43 cases. Indian J Pathol Microbiol 2009;52:357-59.
18. Iram Qazi, Naina K Dogra, Devraj Dogra, Melasma: A Clinical and Epidemiological Study.International Journal of Contemporary Medical Research 2017.
19. Tehranchinia Z, Saghi B, Rahimi H. Evaluation of therapeutic efficacy and safety of tranexamic acid local infiltration in combination with topical 4% hydroquinone cream compared to topical 4% hydroquinone cream alone in patients with melasma: a split-face study. Dermatology research and practice 2018;2018.
20. Padhi T, Pradhan S. Oral tranexamic acid with fluocinolone-based triple combination cream versus fluocinolone-based triple combination cream alone in melasma: An open labeled randomized comparative trial. Indian journal of dermatology 2015;60(5):520.
21. Taraz M, Niknam S, Ehsani AH. Tranexamic acid in treatment of melasma: A comprehensive review of clinical studies. Dermatologic therapy 2017;30(3):e12465.
22. Kim MS, Bang SH, Kim J-H, Shin H-J, Choi J-H, Chang SE. Tranexamic acid diminishes laser-induced melanogenesis. Annals of dermatology 2015;27(3):250.
23. Lee HC, Thng TGS, Goh CL. Oral tranexamic acid (TA) in the treatment of melasma: a retrospective analysis. Journal of the American Academy of Dermatology 2016;75(2):385-92.
24. Karn D, Kc S, Amatya A, Razouria E, Timalsina M. Oral tranexamic acid for the treatment of melasma. Kathmandu University Medical Journal 2012;10(4):40-3.
25. Elfar N, El-Maghraby G. Efficacy of intradermal injection of tranexamic acid, topical silymarin and glycolic acid peeling in treatment of melasma: A comparative study. J Clin Exp Dermatol Res 2015;6(280):2.
Downloads
Published
Issue
Section
License
Copyright (c) 2023 Faisal Ramzan, Khadija Malik, Bushra Bashir, Zaeema Naseer, Atif Shehzad, Lamees Malik, Tariq Rashid
This work is licensed under a Creative Commons Attribution 4.0 International License.
Submission declaration
Authors retain the copyright to their work and grant the 'Journal of Pakistan Association of Dermatologists (JPAD)' the right of first publication under a Creative Commons Attribution 4.0 International (CC BY 4.0) license. This license allows others to share, adapt, and reuse the work for any purpose, including commercial use, as long as appropriate credit is given to the original authors and the journal.
By submitting a manuscript, authors confirm that the work has not been published previously (except as an abstract, lecture, or academic thesis), is not under review elsewhere, and has been approved by all authors and relevant authorities. Once accepted, the article will be openly accessible under the CC BY 4.0 license, ensuring wide dissemination and reuse with proper attribution.
